Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01607073 · ClinicalTrials.gov registry record · Phase 2
Verapamil as Therapy for Children and Young Adults With Dravet Syndrome
A Phase 2 study of Dravet Syndrome, sponsored by Gillette Children's Specialty Healthcare.
- Completed
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
- 4
- Study locations
NCT01607073: Completed Phase 2 study of Dravet Syndrome, sponsored by Gillette Children's Specialty Healthcare.
NCT01607073 is a Phase 2 study of Dravet Syndrome that has completed, run by Gillette Children's Specialty Healthcare. The registered enrollment target is 2 participants, below the 110-participant average among 12 other Dravet Syndrome trials with a reported enrollment target (98% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01607073, a Phase 2 study of Dravet Syndrome, has completed, sponsored by Gillette Children's Specialty Healthcare.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study will assess how well the drug verapamil can improve control of seizures and dysautonomia symptoms in children and young adults diagnosed with Dravet syndrome. The safety of verapamil when given with all concomitant medications will also be assessed.
Primary Outcome
The primary study endpoint is the change in number of seizures from baseline. Since we only had one participant finish the study, the endpoint was changed to Week 12 visit. Participants were on verapamil for 4 weeks at Week 12.
Conditions Studied
Interventions
- DRUG Verapamil
Study Locations (4)
Minnesota
- Mayo Clinic - Rochester
- Gillette Children's Specialty Healthcare - Saint Paul
Illinois
- Children's Memorial Hospital - Chicago
New Hampshire
- Mary Hitchcock Memorial Hospital - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2012-04 |
| Est. Completion | 2015-01 |
| Phase | Phase 2 |
What the finished NCT01607073 record still lists
NCT01607073 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 110-participant average among 12 other Dravet Syndrome trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Dravet Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Verapamil is the first listed.
NCT01607073 reports a single indexed study location in Minnesota, Illinois, New Hampshire.
Frequently Asked Questions
What is clinical trial NCT01607073 about?
NCT01607073 is a clinical study titled "Verapamil as Therapy for Children and Young Adults With Dravet Syndrome". This study will assess how well the drug verapamil can improve control of seizures and dysautonomia symptoms in children and young adults diagnosed with Dravet syndrome. The safety of verapamil when given with all concomitant medications will also be assessed.
What is the current status of trial NCT01607073?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2012-04. Estimated completion is 2015-01.
What conditions does trial NCT01607073 study?
This clinical trial studies the following conditions: Dravet Syndrome.
What interventions are being tested in trial NCT01607073?
The interventions under investigation include: Verapamil (DRUG).
Who is sponsoring clinical trial NCT01607073?
This trial is sponsored by Gillette Children's Specialty Healthcare, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01607073 being conducted?
This trial has 4 study locations across Illinois, Minnesota, New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dravet Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01607073's enrollment target sits among peer trials
2 13th of 12 the lowest of 12 other Dravet Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dravet Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome
ACTIVE NOT RECRUITING · Phase 2
-
Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy
COMPLETED · Phase 2
-
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
RECRUITING · Phase 3
-
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
RECRUITING · Phase 1
-
A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
RECRUITING · Phase 3
-
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia